#### 1 Multi-omics characterization of type 2 diabetes associated genetic variation.

- 2
- 3 Ravi Mandla<sup>1,2,3\*</sup>†, Kim Lorenz<sup>4,5,6,7\*</sup>, Xianyong Yin<sup>8,9\*</sup>, Ozvan Bocher<sup>10\*</sup>, Alicia Huerta-
- 4 Chagoya<sup>1,3\*</sup>, Ana Luiza Arruda<sup>10,11\*</sup>, Anthony Piron<sup>12,13,14,15\*</sup>, Susanne Horn<sup>10\*</sup>, Ken Suzuki<sup>16,17,18</sup>,
- 5 Konstantinos Hatzikotoulas<sup>10</sup>, Lorraine Southam<sup>10</sup>, Henry Taylor<sup>19,20,21</sup>, Kaiyuan Yang<sup>22,23</sup>, Karin
- 6 Hrovatin<sup>24,25</sup>, Yue Tong<sup>26</sup>, Maria Lytrivi<sup>26,27</sup>, Nigel W. Rayner<sup>10</sup>, James B. Meigs<sup>1,28,29</sup>, Mark I.
- 7 McCarthy<sup>30,31,32</sup>, Anubha Mahajan<sup>30,31</sup>, Miriam S. Udler<sup>1,2,3,28</sup>, Cassandra N. Spracklen<sup>33</sup>, Michael
- 8 Boehnke<sup>9</sup>, Marijana Vujkovic<sup>4,34,35</sup>, Jerome I. Rotter<sup>36</sup>, Decio L. Eizirik<sup>26</sup>, Miriam
- 9 Cnop<sup>26,27,37</sup>#, Heiko Lickert<sup>22,23,38</sup>#, Andrew P. Morris<sup>16,10,39</sup>#†, Eleftheria Zeggini<sup>10,40</sup>#†, Benjamin
- 10 F. Voight<sup>4,5,6,7</sup>†#, Josep M. Mercader<sup>1,2,3,29</sup>†#

#### 11 Affiliations

12 <sup>1</sup>Programs in Metabolism and Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA. <sup>2</sup>Diabetes Unit, Endocrine Division, Department of Medicine, 13 Massachusetts General Hospital, Boston, MA, USA. <sup>3</sup>Center for Genomic Medicine, 14 Massachusetts General Hospital, Boston, MA, USA. <sup>4</sup>Corporal Michael J. Crescenz VA Medical 15 Center, Philadelphia, PA, USA. <sup>5</sup>Department of Systems Pharmacology and Translational 16 17 Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA, <sup>6</sup>Department of Genetics, University of Pennsylvania Perelman School of Medicine, 18 19 Philadelphia, PA, USA. <sup>7</sup>Institute for Translational Medicine and Therapeutics, University of 20 Pennsylvania - Perelman School of Medicine, Philadelphia PA. <sup>8</sup>Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, China. <sup>9</sup>Department of 21 22 Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, MI, USA. 23 <sup>10</sup>Institute of Translational Genomics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany. <sup>11</sup>Graduate School of Experimental Medicine, 24 Technical University of Munich, Munich, Germany. <sup>12</sup>ULB Center for Diabetes Research, 25 Medical Faculty, Université Libre de Bruxelles, Brussels, Belgium. <sup>13</sup>Interuniversity Institute of 26 Bioinformatics in Brussels (IB2), Brussels, Belgium.<sup>14</sup>Machine Learning Group, Université Libre 27 de Bruxelles, Brussels, Belgium. <sup>15</sup>Diabetes and Inflammation Laboratory, Centre for Human 28 29 Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom. 30 <sup>16</sup>Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, 31 Division of Musculoskeletal and Dermatological Sciences, University of Manchester, Manchester, UK. <sup>17</sup>Department of Diabetes and Metabolic Diseases, Graduate School of 32 Medicine, University of Tokyo, Tokyo, Japan.<sup>18</sup>Department of Statistical Genetics, Osaka 33 University Graduate School of Medicine, Suita, Japan.<sup>19</sup>Center for Precision Health Research, 34 35 National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA. <sup>20</sup>British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. <sup>21</sup>Heart and Lung Research Institute, 36 37 University of Cambridge, Cambridge, UK. <sup>22</sup>Institute of Diabetes and Regeneration Research 38 (IDR), Helmholtz Munich, Neuherberg, Germany.<sup>23</sup>German Center for Diabetes Research 39 (DZD), Neuherberg, Germany.<sup>24</sup>Institute of Computational Biology (ICB), Helmholtz Munich. 40

Neuherberg, Germany. <sup>25</sup>School of Life Sciences Weihenstephan, Technical University of 41 Munich, Freising, Germany.<sup>26</sup>ULB Center for Diabetes Research, Medical Faculty, Université 42 Libre de Bruxelles, Brussels, Belgium.<sup>27</sup>Division of Endocrinology, Erasmus Hospital, Universite 43 Libre de Bruxelles, Brussels, Belgium.<sup>28</sup>Department of Medicine, Harvard Medical School, 44 Boston, MA, USA. <sup>29</sup>Division of General Internal Medicine, Massachusetts General Hospital, 45 Boston, MA, USA. <sup>30</sup>Wellcome Centre for Human Genetics, Nuffield Department of Medicine, 46 University of Oxford, Oxford, UK. <sup>31</sup>Oxford Centre for Diabetes, Endocrinology and Metabolism, 47 Radcliffe Department of Medicine, University of Oxford, Oxford, UK, <sup>32</sup>Oxford NIHR Biomedical 48 Research Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, 49 50 Oxford, UK. <sup>33</sup>Department of Biostatistics and Epidemiology, University of Massachusetts Amherst, Amherst, MA, USA.<sup>34</sup>Department of Medicine, University of Pennsylvania Perelman 51 School of Medicine, Philadelphia, PA, USA. <sup>35</sup>Department of Biostatistics, Epidemiology and 52 53 Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. 54 <sup>36</sup>Institute for Translational Genomics and Population Sciences, Department of Pediatrics, 55 Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA. <sup>37</sup> WEL Research Institute, Wavre, Belgium. <sup>38</sup>School of Medicine, Technical University of 56 Munich, Munich, Germany.<sup>39</sup>Estonian Genome Centre, Institute of Genomics, University of 57 Tartu, Tartu, Estonia. <sup>40</sup>TUM School of Medicine and Health, Technical University of Munich and 58 Klinikum Rechts der Isar, Munich, Germany. \*These authors contributed equally to this work. 59 60 #These authors supervised this work. †Correspondence to: rmandla@broadinstitute.org, 61 andrew.morris-5@manchester.ac.uk. eleftheria.zeggini@helmholtz-muenchen.de. 62 bvoight@upenn.edu, mercader@broadinstitute.org.

63

64

#### 65 Abstract

Discerning the mechanisms driving type 2 diabetes (T2D) pathophysiology from genome-wide 66 67 association studies (GWAS) remains a challenge. To this end, we integrated omics information 68 from 16 multi-tissue and multi-ancestry expression, protein, and metabolite quantitative trait loci 69 (QTL) studies and 46 multi-ancestry GWAS for T2D-related traits with the largest, most 70 ancestrally diverse T2D GWAS to date. 71 Of the 1,289 T2D GWAS index variants, 716 (56%) demonstrated strong evidence of 72 colocalization with a molecular or T2D-related trait, implicating 657 cis-effector genes, 1,691 73 distal-effector genes, 731 metabolites, and 43 T2D-related traits. We identified 773 of these cis-74 and distal-effector genes using either expression QTL data from understudied ancestry groups 75 or inclusion of T2D index variants enriched in underrepresented populations, emphasizing the 76 value of increasing population diversity in functional mapping. Linking these variants, genes, 77 metabolites, and traits into a network, we elucidated mechanisms through which T2D-78 associated variation may impact disease risk. Finally, we showed that drugs targeting effector 79 proteins were enriched in those approved to treat T2D, highlighting the potential of these results 80 to prioritize drug targets for T2D. 81 These results represent a leap in the molecular characterization of T2D-associated genetic 82 variation and will aid in translating genetic findings into novel therapeutic strategies. 83

#### 84 Introduction

Type 2 diabetes (T2D) and its associated complications are one of the biggest global health problems of the 21<sup>st</sup> century<sup>1,2</sup>. The biological mechanisms underlying T2D are not fully understood, yet expanding upon pathways for T2D could inform therapeutic approaches. It has been demonstrated that clinical trials of drugs that have genetic support are more likely to be successful and to be granted expedited development and review by the FDA<sup>3-6</sup>. Therefore, a

logical approach to accelerate development of new T2D drugs is through linking T2D-associated
 variants with their effector genes.

92

93 One strategy to nominate potential disease effector genes is to identify rare variants that alter 94 the protein coding sequence through putative loss-of-function (pLOF) or amino-acid altering variants<sup>7,8</sup>. While this approach has generated numerous leads<sup>9</sup>, discovery of rare coding 95 96 variants associated with T2D has been limited by small sample sizes from available exome or 97 genome sequencing studies, especially in underrepresented populations. In contrast, large-98 scale multi-ancestry array-based genome-wide association studies (GWAS) have been successful in identifying hundreds of genetic associations<sup>10–15</sup>. However, only 50 (4%) of the 99 100 1,289 T2D-associated genetic variants from the latest T2D GWAS are themselves a pLOF or amino-acid altering variant<sup>15</sup>. Previous results have also suggested only 43% of T2D-associated 101 protein-altering variants show evidence of causality after fine-mapping<sup>16</sup>, complicating efforts 102 103 with this strategy alone to identify the effector genes underlying most T2D associations. 104 Additionally, inference of the tissue of action, effect direction, and physiological mechanisms of 105 T2D-associated variants are also important to translate these discoveries into mechanistic 106 insights and novel drug targets.

107

108 Many T2D variant-to-function efforts have attempted to determine these downstream targets 109 through the identification of shared causal signals underlying both T2D and a single omics layer 110 from a quantitative trait loci (QTL) analysis, with gene expression being the most common<sup>17-20</sup>. 111 However, a recent GWAS for T2D could only map *cis*-effector genes for 21% of their signals when using transcriptomic and proteomic data<sup>11</sup>, motivating the pursuit of integrating larger and 112 113 more ancestrally diverse molecular data to identify additional mechanisms. To date, few studies 114 in T2D have attempted to jointly analyze transcriptomic, proteomic, and metabolomic data to link 115 genetic variations to T2D biological pathways. Furthermore, there have been limited attempts to

116	explore the overlap of these functional genomics datasets with cardiometabolic trait-associated
117	clusters for T2D <sup>15,21</sup> to better characterize the biology underlying T2D heterogeneity. More
118	importantly, previous analyses have focused on populations genetically similar to European
119	ancestry individuals from the 1000 Genomes Project (1000G), which we henceforth refer to as
120	EUR-like, limiting our understanding of the biological downstream effects of T2D in other
121	population groups such as those genetically similar to African ancestry (AFR-like), admixed-
122	American (AMR-like), East Asian ancestry (EAS-like), and South asian ancestry (SAS-like).
123	
124	Here, we tested for colocalization between the largest, recently reported multi-ancestry T2D
125	GWAS meta-analysis <sup>15</sup> with association datasets for transcriptomic, proteomic, and
126	metabolomic traits to identify effector transcripts and downstream targets for T2D across
127	multiple tissues and ancestry groups. Additionally, we used GWAS data from T2D-related traits,
128	including glycemic, cardiometabolic, and anthropometric traits, to understand the physiological
129	mechanisms linked to T2D-associated variation and to further characterize the heterogeneity of
130	T2D loci. We found evidence of colocalization between T2D signals and molecular or T2D-
131	related traits for the majority of the T2D signals, expanding the catalog of variant-to-gene
132	mappings and physiologic correlates with disease. We combined these associations into an
133	interactive network to define relationships between genetic variants, molecular trait data, and
134	T2D-related traits, providing a resource to prioritize mechanisms and propose potential
135	therapeutic hypotheses.
136	

137 **Results** 

138 Overall analysis strategy

To understand molecular mechanisms and physiological mechanisms of T2D-associated
 genetic variation, we evaluated evidence of pairwise-colocalization between each of the 1,289
 T2D-associated index variants identified in Suzuki et al.<sup>15</sup> and *cis*-gene expression QTL from

142	diverse tissues and ancestries (eQTL, 10 datasets), protein QTL (cis- and trans-pQTL, 4
143	datasets), metabolite QTL (metabQTL, 2 datasets), and T2D-related cardiometabolic trait
144	GWAS (46 datasets; Fig. 1a; Supplementary Tables 1 and 2; Methods). We identified 12,180
145	colocalizations with a posterior probability of a shared causal variant (PP.H4) > 0.8,
146	corresponding to a total of 716 T2D index variants colocalizing with 657 cis-effector genes from
147	an eQTL or <i>cis</i> -pQTL, 1,691 distal-effector genes from <i>trans</i> -pQTL, 731 metabolites, and 43
148	T2D-related traits (Fig. 1b, 1c; Supplementary Tables 3, 4, 5, and 6; Methods).
149	
150	We represented the 12,180 colocalizations as a multi-layer colocalization network, where nodes
151	represent T2D GWAS index variants, genes, metabolites, or traits, and edges represent a
152	colocalization between T2D and eQTLs, pQTLs, metabQTLs or trait GWAS data (Fig. 1a;
153	Supplementary File).
154	
155	Identification of T2D cis-effector genes and their relevant tissues
155 156	<i>Identification of T2D cis-effector genes and their relevant tissues</i> To identify candidate T2D effector genes and their tissues of action, we tested for evidence of
155 156 157	<i>Identification of T2D cis-effector genes and their relevant tissues</i> To identify candidate T2D effector genes and their tissues of action, we tested for evidence of colocalization between T2D and eQTL datasets from blood <sup>22,23</sup> and six T2D-related tissues:
155 156 157 158	Identification of T2D cis-effector genes and their relevant tissues To identify candidate T2D effector genes and their tissues of action, we tested for evidence of colocalization between T2D and eQTL datasets from blood <sup>22,23</sup> and six T2D-related tissues: pancreatic islets <sup>19</sup> , subcutaneous and visceral adipose tissue, liver, hypothalamus, and skeletal
155 156 157 158 159	Identification of T2D cis-effector genes and their relevant tissues To identify candidate T2D effector genes and their tissues of action, we tested for evidence of colocalization between T2D and eQTL datasets from blood <sup>22,23</sup> and six T2D-related tissues: pancreatic islets <sup>19</sup> , subcutaneous and visceral adipose tissue, liver, hypothalamus, and skeletal muscle <sup>23</sup> (Methods). We observed 1,324 colocalizations, representing 632 candidate <i>cis</i> -
155 156 157 158 159 160	<i>Identification of T2D cis-effector genes and their relevant tissues</i> To identify candidate T2D effector genes and their tissues of action, we tested for evidence of colocalization between T2D and eQTL datasets from blood <sup>22,23</sup> and six T2D-related tissues: pancreatic islets <sup>19</sup> , subcutaneous and visceral adipose tissue, liver, hypothalamus, and skeletal muscle <sup>23</sup> ( <b>Methods</b> ). We observed 1,324 colocalizations, representing 632 candidate <i>cis</i> -effector genes, and 349 (27.1%) of the 1,289 T2D index variants. Of the 349 index variants, 110
155 156 157 158 159 160 161	Identification of T2D cis-effector genes and their relevant tissues To identify candidate T2D effector genes and their tissues of action, we tested for evidence of colocalization between T2D and eQTL datasets from blood <sup>22,23</sup> and six T2D-related tissues: pancreatic islets <sup>19</sup> , subcutaneous and visceral adipose tissue, liver, hypothalamus, and skeletal muscle <sup>23</sup> (Methods). We observed 1,324 colocalizations, representing 632 candidate <i>cis</i> - effector genes, and 349 (27.1%) of the 1,289 T2D index variants. Of the 349 index variants, 110 (32.0%) colocalized to different effector genes in different tissues, suggesting evidence of
155 156 157 158 159 160 161 162	<i>Identification of T2D cis-effector genes and their relevant tissues</i> To identify candidate T2D effector genes and their tissues of action, we tested for evidence of colocalization between T2D and eQTL datasets from blood <sup>22,23</sup> and six T2D-related tissues: pancreatic islets <sup>19</sup> , subcutaneous and visceral adipose tissue, liver, hypothalamus, and skeletal muscle <sup>23</sup> (Methods). We observed 1,324 colocalizations, representing 632 candidate <i>cis</i> -effector genes, and 349 (27.1%) of the 1,289 T2D index variants. Of the 349 index variants, 110 (32.0%) colocalized to different effector genes in different tissues, suggesting evidence of varying effects by tissue (Supplementary Table 7).
155 156 157 158 159 160 161 162 163	<i>Identification of T2D cis-effector genes and their relevant tissues</i> To identify candidate T2D effector genes and their tissues of action, we tested for evidence of colocalization between T2D and eQTL datasets from blood <sup>22,23</sup> and six T2D-related tissues: pancreatic islets <sup>19</sup> , subcutaneous and visceral adipose tissue, liver, hypothalamus, and skeletal muscle <sup>23</sup> ( <b>Methods</b> ). We observed 1,324 colocalizations, representing 632 candidate <i>cis</i> -effector genes, and 349 (27.1%) of the 1,289 T2D index variants. Of the 349 index variants, 110 (32.0%) colocalized to different effector genes in different tissues, suggesting evidence of varying effects by tissue ( <b>Supplementary Table 7</b> ).
155 156 157 158 159 160 161 162 163 164	Identification of T2D cis-effector genes and their relevant tissues To identify candidate T2D effector genes and their tissues of action, we tested for evidence of colocalization between T2D and eQTL datasets from blood <sup>22,23</sup> and six T2D-related tissues: pancreatic islets <sup>19</sup> , subcutaneous and visceral adipose tissue, liver, hypothalamus, and skeletal muscle <sup>23</sup> (Methods). We observed 1,324 colocalizations, representing 632 candidate <i>cis</i> - effector genes, and 349 (27.1%) of the 1,289 T2D index variants. Of the 349 index variants, 110 (32.0%) colocalized to different effector genes in different tissues, suggesting evidence of varying effects by tissue (Supplementary Table 7). To quantify the improvement in our list of T2D effector genes, we compared our results to
155 156 157 158 159 160 161 162 163 164 165	Identification of T2D cis-effector genes and their relevant tissues To identify candidate T2D effector genes and their tissues of action, we tested for evidence of colocalization between T2D and eQTL datasets from blood <sup>22,23</sup> and six T2D-related tissues: pancreatic islets <sup>19</sup> , subcutaneous and visceral adipose tissue, liver, hypothalamus, and skeletal muscle <sup>23</sup> (Methods). We observed 1,324 colocalizations, representing 632 candidate <i>cis</i> - effector genes, and 349 (27.1%) of the 1,289 T2D index variants. Of the 349 index variants, 110 (32.0%) colocalized to different effector genes in different tissues, suggesting evidence of varying effects by tissue (Supplementary Table 7). To quantify the improvement in our list of T2D effector genes, we compared our results to previous studies that performed colocalization analyses on different T2D GWAS <sup>11,14,19,24</sup> . We
<ol> <li>155</li> <li>156</li> <li>157</li> <li>158</li> <li>159</li> <li>160</li> <li>161</li> <li>162</li> <li>163</li> <li>164</li> <li>165</li> <li>166</li> </ol>	Identification of T2D cis-effector genes and their relevant tissues To identify candidate T2D effector genes and their tissues of action, we tested for evidence of colocalization between T2D and eQTL datasets from blood <sup>22,23</sup> and six T2D-related tissues: pancreatic islets <sup>19</sup> , subcutaneous and visceral adipose tissue, liver, hypothalamus, and skeletal muscle <sup>23</sup> (Methods). We observed 1,324 colocalizations, representing 632 candidate <i>cis</i> - effector genes, and 349 (27.1%) of the 1,289 T2D index variants. Of the 349 index variants, 110 (32.0%) colocalized to different effector genes in different tissues, suggesting evidence of varying effects by tissue (Supplementary Table 7). To quantify the improvement in our list of T2D effector genes, we compared our results to previous studies that performed colocalization analyses on different T2D GWAS <sup>11,14,19,24</sup> . We found that the present analysis doubles the number of candidate effector genes compared to

168	and the new and larger eQTL datasets we employed (Fig. 2a). Indeed, the number of
169	colocalizations per eQTL dataset was strongly correlated with the eQTL dataset sample size
170	(Pearson r=0.79, $P$ =6.8×10 <sup>-3</sup> ), highlighting the importance of statistical power in colocalization
171	analyses (Extended Data Fig. 1).
172	
173	We observed many colocalizations in a single tissue only (Fig. 2b) with pancreatic islets having
174	the highest proportion of single-tissue observed colocalizations (0.50; Fig. 2c). One of the
175	colocalizations only observed in pancreatic islets was with SCTR, a G-protein-coupled receptor
176	in the same family as known T2D drug target GLP1R (Fig. 2d). SCTR is highly and specifically
177	expressed in pancreatic islets <sup>19</sup> and is downregulated in pancreatic islets of T2D patients <sup>25</sup> ,
178	supporting the relevance of pancreatic islet expression of SCTR in T2D pathophysiology. SCTR
179	also harbors a missense variant associated with lower T2D risk <sup>12,13</sup> that is enriched in EAS-like
180	populations.
181	
182	To validate the candidate effector genes colocalizing with T2D in islets, we performed gene set
183	enrichment analyses between differentially expressed T2D genes in islets and these effector
184	genes stratified by the direction of effect for the T2D risk allele (Supplementary Table 8;
185	Methods). We found that genes from colocalizations where decreased expression is associated
186	with increased T2D risk are significantly enriched in genes downregulated in islets of T2D cases
187	(Normalized Enrichment Score [NES]=-1.7; P=0.01) (Extended Data Fig. 2). Enrichment only in
188	the colocalizations where the risk allele reduces expression may indicate a large abundance of
189	associations between diminished gene function and T2D risk.
190	
191	pQTL colocalization identifies additional cis and trans effector proteins

192 To expand our identification of effector genes beyond eQTLs, we tested for evidence of

193 colocalization between T2D and four pQTL datasets (plasma UKB, plasma deCODE, plasma

HELIC, and brain ROS/MAP). We identified 42 and 3,423 colocalizations with a *cis*-pQTL and
 *trans*-pQTL respectively, encompassing 1,728 unique genes and 365 (28.3%) T2D index
 variants.

197

198 We identified most of the colocalizations (2,451, 70.7%) with pQTLs from the deCODE dataset, 199 which had the second largest sample size but included more proteins, owing to the use of the 200 Somascan panels (N=35,559; N<sub>proteins</sub>=4,907), compared with the OLINK panels employed by 201 the UKB data (N=54,219, N<sub>proteins</sub>=1,472; Fig. 3a). We also observed 85 colocalizations with the 202 HELIC data (N=2,933) and 7 with the ROS/MAP data (N=330). Despite differences in sample 203 size and protein sets, we observed 37 identical colocalizations (all in *trans*) with deCODE and 204 UKB pQTL datasets, which is 7.5-fold higher than expected by chance considering the overlap 205 of proteins detected by both the Somascan and OLINK panels (Fisher's exact test  $P=7.4\times10^{-20}$ ; 206 Methods; Supplementary Table 9). Among those 37, we found strong consistency of protein effect size estimates between deCODE and UKB (Pearson r=0.93; P=9.1×10<sup>-17</sup>; Fig. 3b). One 207 208 example colocalization detected with both UKB and deCODE pQTL datasets was for CBLN4 209 with T2D index variant rs1415287 in trans, within the LYPLAL1 locus defined in Suzuki et al.<sup>15</sup>. 210 where the risk allele associated with increased levels of CBLN4 (Fig. 3c). rs1415287 211 additionally colocalized with IGFBP-1 in trans (Fig. 3d), with decreased IGFBP-1 levels 212 associated with the T2D risk allele. A previous study found decreased CBLN4 and increased 213 IGFBP-1 plasma levels after administering SGLT2 inhibitors, a class of T2D drugs which 214 reduces glucose reabsorption within the proximal renal tubule, to participants of varying glucose 215 tolerance<sup>26</sup>, mirroring our findings of increased CBLN4 and decreased IGFBP-1 levels with the 216 T2D risk allele.

217

We also identified 784 genes for which there was a pQTL colocalizing with more than one T2D index variant (**Extended Data Fig. 3a**). We ranked these genes based on the association

220 between the pQTL and T2D GWAS effect sizes across all index variants that colocalized with a 221 given gene (Supplementary Table 10, Methods). Among the highest ranked genes, IGFBP2 222 had 14 colocalizations with overall negative associations between T2D-associated index variant 223 risk allele effect size and protein levels, supporting previously reported negative associations between IGFBP-2 levels and T2D incidence<sup>27</sup> (**Extended Data Fig. 3b**). Seven of these index 224 225 variants (50%) have previously been classified as being involved in lipodystrophy-related 226 pathways<sup>15</sup>, suggesting IGFBP-2 may be involved lipodystrophy-like T2D. In agreement with 227 that, previous publications have found associations between increased IGFBP-2 and lower BMI, lower waist-hip ratio, and increased triglycerides<sup>28</sup> and decreased NAFLD risk<sup>29,30</sup>. Together, 228 229 these results highlight the value of highly powered pQTL datasets in identifying biologically 230 relevant effector genes.

231

232 Inclusion of understudied population datasets boosts effector gene identification 233 In the latest multi-ancestry T2D meta-analysis, 289 index variants (22.4%) have a MAF half as large in EUR-like populations compared to other populations<sup>15</sup>, in total mapping to 615 effector 234 235 genes from a previously-described T2D-relevant tissue eQTL colocalization or pQTL 236 colocalization. However, identifying effector genes for variants enriched in underrepresented 237 populations remains a challenge due to a lack of molecular data from the same population<sup>31</sup>. To 238 quantify the extent to which including molecular data from underrepresented populations 239 improves the discovery of effector genes, we tested for colocalization between blood eQTL 240 datasets collected in self-reported African American (AA), Mexican American (MX), and Puerto Rican (PR) cohorts<sup>22</sup> and the EUR-like GTEx dataset with both the multi-ancestry T2D GWAS 241 242 and with matched ancestry T2D GWAS containing only AFR-like participants within the USA or 243 AMR-like participants. We identified 633 colocalizations with one of these eQTL datasets 244 (47.8% of all eQTL colocalizations), representing 347 gene-to-variant mappings. We identified 245 204 (58.8%) of the 347 blood eQTL mappings in the AA, MX, or PR eQTL datasets only, and 37

246 (10.7%) only in the EUR-like GTEx dataset (Fig. 4a; Methods; Supplementary Table 11). In 247 total, adding the AA, MX, or PR eQTL data identified 158 additional T2D effector genes not 248 identified with any of the tested EUR-like eQTL or pQTL datasets, highlighting the importance of 249 collecting data from underrepresented populations, even when testing a tissue that is not 250 directly relevant for T2D pathophysiology. We found that T2D index variants with a 251 colocalization observed only with an AA, MX, or PR blood eQTL were more common in AMR-252 like participants and less common in EUR-like participants relative to T2D index variants with a 253 colocalization observed only with the EUR-like GTEx blood eQTL dataset (Fig. 4b; P=0.02). 254 These results suggest differences in statistical power due to allele frequency heterogeneity 255 and/or varying linkage diseguilibrium (LD) with the true causal variant may underly differential 256 detection of colocalizations across ancestry groups. 257 258 Two example colocalizations observed only in the MX blood eQTL data were with LIN7A and 259 ACSS3, both with the same lead variant from colocalization analyses, rs10128882 (Fig. 4c). 260 The LD between rs10128882 and the T2D GWAS index variant rs11114650 was different 261 between ancestry groups, with the highest being in EAS-like individuals ( $r^2$ =0.89) and the lowest in AFR-like individuals ( $r^2=0.02$ ), possibly reflecting differential LD to the true causal variant 262 263 across populations. The T2D risk allele of rs11114650 has a frequency of 1.5% in gnomAD-264 defined European populations compared to 39% in gnomAD-defined African populations (Fig. 265 4d) and is associated with decreased blood expression levels of LIN7A and ACSS3 (Fig. 4e). 266 LIN7A, mainly expressed in the brain, is involved in localizing, distributing, and maintaining channels and receptors at polarized cell membranes<sup>32</sup>, while ACSS3 is highly expressed in 267 268 brown adipose tissue and has been previously associated with insulin-resistant obesity-like phenotypes in mice<sup>33</sup>. 269

270

271 Identification of effector metabolites

272 To understand the metabolic processes of T2D-associated genetic variation, we tested for colocalization between T2D GWAS and plasma metabQTL data from UKB and the METSIM 273 274 study. We identified 5,221 metabQTL colocalizations, corresponding to 283 T2D index variants, 275 with a majority of these colocalizations (4,480, 85.8%) with the UKB metabQTL data. This is 276 expected given the larger sample size of the UKB data (N=114,999) compared to the METSIM 277 data (N=6.136). Of the 18 metabolites measured in the METSIM Metabolon panel that could be 278 mapped to metabolites in the UKB Nightingale panel, 7 colocalized with the T2D GWAS in both 279 METSIM and UKB, an overlap greater than expected by chance (Fisher's exact test OR=26.2,  $P=1.8\times10^{-7}$ ; Methods; Supplementary Table 12), suggesting good concordance between the 280 281 two platforms for shared metabolites.

282

283 To prioritize metabolites with the largest implication with T2D, we ranked metabolites by the 284 number of T2D index variants with which they colocalize, and by the association of genetic 285 effect sizes between T2D and metabolites across all the index variants that colocalized with 286 each metabolite (Fig. 5a; Supplementary Table 13; Methods). We found consistent 287 associations between the risk allele effects and expected metabolite levels, such as T2D risk 288 alleles associated with increased glucose levels (Fig. 5a, 5b). Among less well-established 289 metabolites, we found 10 colocalizations where the T2D risk alleles lowered phosphatidylcholine 290 levels (Fig. 5c), consistent with higher phosphatidylcholine intake previously associated with 291 lower risk of T2D<sup>34,35</sup>. A subnetwork of all phosphatidylcholine-linked colocalizations was 292 enriched for metabolites known to be related to phosphatidylcholine metabolism, such as sphingomyelin ( $P_{adi}$ =0.02), cholines ( $P_{adi}$ =2.4×10<sup>-17</sup>), and polyunsaturated fatty acids (PUFAs) 293 294 (P<sub>adi</sub>=0.02; Fig. 5d; Supplementary Table 14; Methods). Within this subnetwork, SMPD1 295 (sphingomyelin phosphodiesterase 1) protein levels also colocalized with 4 of the same 10 T2D 296 index variants, including two detected in two plasma pQTL studies (UKB pQTL and deCODE 297 pQTL for rs9987289 and UKB pQTL and HELIC pQTL for rs8107974), providing robustness to

298	these results. SMPD1 acts in the same biochemical pathways as phosphatidylcholine synthesis
299	and, along with PUFAs, has previously been associated with diabetic complications including
300	diabetic retinopathy <sup>36</sup> . Combined, these results highlight the role of phosphatidylcholine
301	metabolic pathways in T2D.
302	
303	Colocalization with T2D-related traits recapitulates previously described T2D genetic
304	clusters
305	We next performed colocalization analyses between T2D and 46 T2D-related traits to shed light
306	into distinct T2D pathophysiologic mechanisms. We identified 2,170 colocalizations, including
307	521 (40.4%) of the T2D index variants and 43 traits.
308	
309	Previously, Suzuki et al. grouped T2D index variants based on their associations with a smaller
310	subset of 37 of these traits to define 8 distinct genetic T2D mechanistic clusters (Beta cell with
311	positive proinsulin, Beta cell with negative proinsulin, Residual glycaemic, Body fat, Metabolic
312	syndrome, Obesity, Lipodystrophy, Liver/lipid metabolism). Their analyses used a k-means
313	clustering approach on the Z-scores of the T2D index variants from each of the 37 T2D-related
314	trait GWAS <sup>15</sup> . We expanded on this work by assessing the proportion of T2D index variants per
315	cluster which could be mapped to a colocalization between T2D and at least one of the 37 traits
316	previously used for clustering. We found that the Obesity cluster had the highest number of
317	variants confirmed by colocalization, with 163 (70%) of the 223 index variants colocalizing with
318	at least one of the 37 traits, reflecting the large number of obesity-related traits considered
319	during colocalization testing. The colocalizing trait patterns also largely recapitulated the single-
320	variant association-derived clusters <sup>15</sup> ( <b>Fig. 6a</b> , left panel).
321	

We also tested the enrichment of eQTL colocalization from different tissues and metabQTL
 colocalizations in each of the clusters. We observed enrichment of subcutaneous adipose tissue

324	colocalizations with the Metabolic syndrome cluster ( $P=2.2\times10^{-5}$ ) and of the pancreatic islet
325	colocalizations with the Beta Cell +PI cluster ( $P=1.6\times10^{-5}$ ; <b>Extended Data Fig. 4</b> ;
326	Supplementary Table 15). We also observed enrichment of fatty acid metabolites with the
327	Lipodystrophy clusters ( $P=2.0\times10^{-9}$ ), and of glycolysis related metabolites with the Beta Cell +PI
328	cluster ( $P=4.7\times10^{-9}$ ; Extended Data Fig. 4; Supplementary Table 16). When aligning effect
329	allele directions and effect sizes, we again recapitulated cluster patterns from Suzuki et al.
330	based on single variant lookups. The results mirror the effects between Obesity (largely same
331	direction) and Metabolic Syndrome/Lipodystrophy (largely opposite direction) cluster SNPs
332	across anthropometric and adipose traits <sup>15</sup> (Fig. 6a, right panel). As we restricted the analyses
333	to loci that have evidence of colocalization, these results are more specific than those previously
334	presented.
335	
336	Within each cluster, variants showed different patterns of colocalizations with different traits
337	(Fig. 6b). For example, the two Beta Cell clusters have the bulk of their colocalizing variants
338	linked to at least one glycaemic trait, while the variants in the Obesity cluster are linked to
339	anthropometric, adipose, and lipids traits (Extended Data Fig. 5). In contrast, the Lipodystrophy
340	cluster variants are more pleiotropic, with 19 of 27 variants linked to 4 or more trait groups,
341	suggestive of heterogeneity within lipodystrophy-related variants (Fig. 6c).
342	
343	Effector genes are enriched in drug targets for diabetes
344	The prioritization of drugs targeting candidate genes can accelerate clinical translation <sup>5,37,38</sup> . We
345	pulled known drugs which target one of the 2,311 genes identified from a <i>cis</i> -eQTL or a <i>cis</i> - or
346	trans-pQTL colocalization (Methods). Among 1,964 gene-to-drug mappings, consisting of 665

347 drugs listed as approved, not withdrawn and with information on disease indications, and 159 of

our colocalizing genes (**Supplementary Table 17**).

349

350 We tested if drugs targeting any of these genes were enriched with an approved indication for 351 diabetes. We observed a 3.5-fold enrichment for approved diabetes indication within drugs that target our list of effector genes ( $P=4.4\times10^{-10}$ ; Fig. 7a; Methods) and a 2.0-fold enrichment for 352 any diabetes indication within drugs targeting the effector genes ( $P=1.9\times10^{-6}$ : Fig. 7b: 353 354 **Methods**), compared to all other drugs. We then performed the same analysis stratified by the 355 source of colocalization, using lists of 1,681 genes identified only from a pQTLs (*cis* or *trans*), 356 1,654 only from trans pQTLs, or 583 only from eQTLs. Drugs targeting pQTL-only identified genes were enriched for approved T2D drug targets (OR=2.4, P=3.4×10<sup>-4</sup>). Drugs targeting 357 358 eQTL-only identified genes were the most enriched for approved drugs for diabetes (OR=3.9, 359  $P=3.7\times10^{-7}$ ). These results suggest that drugs targeting any of our candidate effector genes are 360 potential candidates for repurposing to treat T2D. Permutation analyses similarly found 361 significant enrichment for diabetes drugs among our genes relative to random sets of genes 362 (Extended Data Fig. 6; Methods). 363 364 Among the genes observed only from an eQTL colocalization, we identified FXYD2 (Fig. 7c)

which has been proposed as a pancreatic beta-cell specific biomarker<sup>39</sup>. FXYD2 modulates Na,K-ATPase activity and cell proliferation<sup>40</sup> and is expressed at the early stages of the human endocrine pancreas development (15 weeks), preceding insulin detection<sup>39</sup>, suggesting a putative role in islet development. We also detected *FXYD2* mRNA expression at the end of the differentiation process of induced pluripotent stem cells into islet-like cells in both bulk and single-cell datasets<sup>28,41-43</sup> (**Extended Data Fig. 7**).

371

The risk allele of the T2D index variant rs529623 was associated with lower expression of *FXYD2* in pancreatic islets<sup>19</sup> (**Fig. 7d**;  $P=3.4\times10^{-7}$ ). We further explored expression differences of *FXYD2* in existing bulk RNA-seq<sup>44</sup> and single-cell RNA-seq<sup>45</sup> (scRNA-seq) from pancreatic

375 islets of human donors with and without T2D (**Methods**). After adjusting for multiple hypothesis 376 testing, FXYD2 was significantly downregulated in pancreatic islets of T2D patients (Fig. 7e) 377 specifically within Beta cells<sup>45</sup> (**Fig. 7f**). There are currently five approved drugs that target 378 FXYD2 but are not approved for diabetes: delanoside, digoxin, digitoxin, acetyldigitoxin, and 379 lanatoside. These drugs potentially could be modified to treat T2D, particularly if further 380 preclinical investigations show indications that they can target and modulate beta cell function. 381 382 We also found multiple other drugs targeting proteins for one of our effector genes which had 383 clinical evidence to support a role in impacting glycemia and may represent possible targets for 384 drug repurposing (Supplementary Table 18). For example, amisulpride, an antagonist for the 385 Serotonin (5-HT) receptor encoded by HTR6, increases pancreatic insulin secretion in healthy controls<sup>46</sup>. We identified HTR6 from a blood trans-pQTL colocalization where the T2D risk allele 386 387 is associated with increased protein levels, consistent with amisulpride, which antagonizes 388 HTR6 and increases insulin secretion. 389

#### 390 Discussion

T2D is a model for complex disease genetics owing to its high prevalence and polygenicity, with
 the largest T2D multi-ancestry meta-analysis to date based on >2.5 million participants,

identifying 1,289 index variants<sup>15</sup>. However, understanding the function of associated variants

from a GWAS is extremely challenging, and only few examples have provided additional

insights into the molecular mechanisms underpinning signals<sup>47–51</sup>. These comprehensive studies

take years to complete, and biological insights from previous studies were mostly described in

397 EUR-like populations<sup>14,18,19,24</sup>, limiting findings for other populations in which T2D risk alleles are

398 now being increasingly reported<sup>11,15</sup>.

399

400 Here, we aimed to create a catalog of effector genes, metabolites, and traits for the 1,289 T2Dassociated index variants. We identified >12,000 colocalizations with T2D across all omics 401 402 layers and T2D associated traits tested. We found *cis*-effector genes for 361 of the index 403 variants (28%) and identified a >2-fold increase in the number of *cis*-effector genes compared with the previous largest T2D GWAS<sup>14</sup>. We observed many of the eQTL colocalizations in only 404 405 one of the tissues tested, emphasizing the importance of including multiple tissue types in 406 variant-to-function efforts for T2D. We also demonstrated the value of multi-ancestry eQTL data 407 through the identification of 158 additional effector genes (24% of all cis-effector genes) using blood eQTL data from AA, PR, and MX populations<sup>22</sup> that we did not observe in eQTL or pQTL 408 409 data from EUR-like populations alone. We demonstrate that even in blood, which is not directly 410 related to T2D progression, including eQTL data from multiple ancestry groups improves 411 effector gene discovery. Despite substantial progress in the inclusion of diverse ancestries in 412 GWAS meta-analysis, the availability of molecular data from diverse ancestries remains limited<sup>31</sup>. We hope that the present findings will help motivate the generation of molecular QTL 413 414 resources from participants of diverse ancestries to unveil additional effector genes and 415 potential drug targets.

416

417 We compiled the pairwise colocalizations between T2D and each omics layer and additional 418 traits to create a network of T2D index variants mapped to genes, metabolites, and traits. This 419 provides the most comprehensive resource to date of the genetic relationships between genes, 420 traits, metabolites, and genetic variants associated with T2D to the research community. Such a 421 resource allows searches for genes, metabolites, or traits of interest and find the T2D index 422 variants underlying their shared causal signals with T2D to quickly generate hypotheses and 423 gain insights into T2D pathophysiology. We additionally include effect and variant information 424 from the molecular QTL, trait GWAS, and T2D GWAS summary statistics to further improve the 425 searchability of the network.

426

427 Identifying drug targets for complex diseases has traditionally focused on protein coding 428 variants, which involves designating the target gene and mimicking a loss-of-function or gain-of-429 function effect<sup>52,53</sup>. However, effector genes regulated by non-coding variants may also be 430 viable drug targets once the mechanism of action is understood. In this study, we identified 431 candidate effector genes, their tissue of action and direction of effect, for potential drug target 432 identification. We show that our list of effector genes is enriched for targets of approved drugs 433 for treatment of T2D, suggesting that drugs not currently used to treat diabetes but targeting one 434 of the effector genes are strong candidates for modification for the treatment of T2D. We 435 acknowledge that additional studies to test causality, druggability, and functional validation with 436 tissue and cell types of interest are needed.

437

438 Our study has limitations. First, we utilized the 1.289 index variants from Suzuki et al. to define 439 our tested colocalization regions, but we recognize that these variants were not assessed for 440 statistical independence applying formal fine-mapping approaches. Second, we leveraged the 441 multi-ancestry meta-analysis for T2D to maximize sample size. However, this approach may 442 underestimate the true number of colocalizations, as we could not perform fine-mapping to 443 differentiate multiple independent signals within the same locus due to current limitations in fine 444 mapping and conditional analyses utilizing only multi-population summary statistics data. Third, 445 confirmation of the tissue of action and the causality and directionality of the effect, especially 446 for distal-effector genes, remains to be determined. This necessitates careful investigation 447 through appropriate causal inference experiments, cellular models, and in vivo studies. To 448 facilitate these efforts, we provide here the most extensive list of effector genes, tissues, and 449 potential physiological pathways linked to T2D associated variation for initial prioritization 450 strategies.

451

In conclusion, we present a comprehensive functional follow-up of the largest T2D GWAS metaanalysis and provide a framework model for functional annotation of other complex multiancestry GWAS. We provide an interactive network to explore the relationships between T2Dassociated variants and genes, metabolites, and traits. We anticipate that this resource will serve as a valuable tool for generating testable hypotheses that may lead to the discovery of novel T2D drug targets and therapeutic strategies.

458

459 Methods

#### 460 **GWAS and Molecular Trait Associated Datasets**

We downloaded GWAS for T2D relevant traits downloaded from a variety of sources described
in Supplementary Table 1<sup>54–70</sup>. We used T2D multi-group meta-analysis generated using
METAL<sup>71</sup> from Suzuki et al.<sup>15</sup> for all colocalization analyses. Additionally, single population
group meta-analyses using METAL from Suzuki et al. for AFR-like participants living within the
USA and for AMR-like participants were used for colocalization. We removed variants with a
MAF <0.5% across all the 1000G-continental similarity groups from the analyses.</li>

467

We downloaded pancreatic Islet eQTL data from TIGER<sup>19</sup>. Since effect size and variance 468 469 information is not available in the TIGER eQTL data, we used p-value information from the 470 summary statistics and allele frequencies from UKB to calculate approximate bayes factors for 471 colocalization analyses. We downloaded eQTL data for subcutaneous adipose, visceral 472 adipose, skeletal muscle, hypothalamus, and liver tissue and blood from GTEx v8. We also 473 tested eQTL data for whole blood from self-reported African American (AA), Mexican American (MX), and Puerto Rican (PR) populations for colocalization<sup>22</sup>. Additionally, we tested T2D 474 475 GWAS including only AFR-like participants from the USA for colocalization with the AA blood 476 eQTL data and tested T2D GWAS including only AMR-like participants for colocalization with 477 the MX and PR blood eQTL datasets. We restricted the colocalization analyses to just these

eQTL datasets as pancreatic islets, subcutaneous adipose, visceral adipose, skeletal muscle,
hypothalamus, and liver are known to be relevant to T2D. Despite blood representing multiple
tissues and not being a target of T2D, the availability of blood eQTL from diverse populations
motivated their inclusion.

482

483 We performed integration with pQTL data using summary statistics from deCODE, UKB, HELIC, 484 and ROS/MAP. The deCODE pQTL study contains 4,907 aptamers measured with the 485 SomaScan version 4 assay (SomaLogic) in the plasma samples of 35.559 Icelanders<sup>72</sup>. The 486 UKB Pharma Proteomics Project characterized 2,941 plasma protein analytes of 54,219 UKB 487 participants using the antibody-based Olink Explore 3072 proximity extension assay and tested 488 for pQTL with 2.923 proteins<sup>73</sup>, pQTL for only 1.472 of these proteins were available at the time 489 of this study. Plasma pQTL from the Hellenic Isolated Cohorts (HELIC)<sup>74</sup> included 2,933 490 samples from two isolated Greek populations (Pomak and the Mylopotamos villages) and 543 491 proteins from six different OLINK panels: Cardiovascular II, Cardiovascular III, Metabolism, Neurology, Neuro-exploratory and Cardiometabolic<sup>75–77</sup>. Genetic and proteomic data from post-492 493 mortem samples of the dorsolateral prefrontal cortex of older adults was provided by the Religious Orders Study (ROS) and Rush Memory and Aging Project (MAP)<sup>78</sup>. The pQTL 494 495 analysis was conducted for every HapMap3 common variant (MAF >0.05) within a 100 Kb 496 window around protein-coding genes.

497

For the colocalization analyses with metabolites, we used summary statistics from the METSIM and UKB cohorts. The METSIM metabolomics study measured 1,391 plasma metabolites in 6,136 Finnish men using the Metabolon Discovery HD4 mass spectrometry platform<sup>79</sup>. In the UKB cohort, a total of 249 metabolites (168 absolute levels and 81 derived ratios and percentages) were measured from the Nightingale panel and tested for genome-wide associations with 114,999 individuals of European ancestry<sup>80</sup>.

504

#### 505 **Colocalization Analyses**

506 We performed pairwise colocalizations between the multi-group T2D GWAS meta-analysis and 507 eQTL, pQTL, metabQTL, and relevant trait GWAS datasets using the coloc.abf function from 508 the coloc<sup>81</sup> package in R. coloc.abf requires regions to be specified to test for colocalization. To 509 define these regions, index variants were sorted by p-value and a 500 Kb window was 510 constructed around each variant. If a less significant index variant was within the window of a 511 more significant variant, the less significant variant's window was removed from the list of 512 regions. To prevent additional overlap of regions, any regions overlapping by more than 200 Kb 513 were merged and regions overlapping by less than 200 Kb were split by half of their overlap 514 size. The final region boundaries used in the analyses can be found in **Supplementary Table 2**. 515 A colocalization analysis was performed between a T2D region and a QTL or cardiometabolic 516 trait if and only if there was evidence of an association (defined as  $P < 1 \times 10^{-4}$ ) of the T2D index 517 variant or a proxy for the T2D index variant for that trait. Proxy variants were defined as a 518 variant in strong linkage disequilibrium (LD,  $r^2 > 0.8$ ) in all continental population groups defined 519 by in 1000G (AFR, AMR, EAS, EUR, and SAS).

520

521 coloc.abf provides the posterior probability that a region shares a causal variant in both 522 association summary statistics tested and posterior probabilities that each variant present in 523 both summary statistics is the causal variant. A colocalization was deemed of interest if the 524 posterior probability or shared variation (PP.H4) was greater than 0.8. To determine if a T2D 525 GWAS index variant is the most likely shared causal variant for a region in two colocalizing 526 datasets, the variant with the highest posterior probability of being shared was mapped to a index variant if it was in partial-to-strong LD with the index variant ( $r^2 > 0.5$ ) in 1000G population 527 528 groups described above.

529

530	We labelled an eQTL colocalization as being observed in one tissue or population group dataset
531	if the PP.H4 was greater than 0.8 in the dataset, but less than 0.3 in all other tissue or
532	population group datasets. A maximum of 0.3 was chosen to avoid selecting suggestive
533	colocalizations that may exist but not be sufficiently powered to be detected with our datasets.
534	For single tissue analyses, we combined subcutaneous adipose and visceral omentum adipose
535	results and combined blood results from each ancestry due to the larger similarities in gene
536	expression profiles between these datasets relative to the other tissues analyzed.
537	
538	We characterized pQTL colocalizations as being in <i>cis</i> if the mapped index variant was within 1
539	Mb of the pQTL gene TSS; otherwise they were denoted as in <i>trans</i> . We tested for enrichment
540	of colocalizations identified between deCODE pQTL which uses the Somascan assay and UKB
541	pQTL which uses the Olink assay, using Fisher's exact test. We constructed contingency tables
542	from all gene to T2D index variant mappings possible for genes included in Somascan and/or
543	Olink respectively. We also used this approach to test for an enrichment of colocalizations
544	identified between METSIM metabQTL and UKB metabQTL, using all metabolite to T2D index
545	variant mappings possible for metabolites included in METSIM and/or UKB respectively.
546	
547	We also tested for enrichment between T2D index variants mapped to an eQTL tissue
548	colocalization and T2D index variants within different T2D genetic clusters using Fisher's exact
549	test. We constructed contingency tables based on whether one of the 1,289 T2D index variants
550	is within a specific T2D genetic cluster and is also the lead colocalizing variant for a
551	colocalization with an eQTL dataset. The Liver/Lipid Metabolism cluster was excluded due to
552	only having 3 total T2D index variants. We then adjusted P-values using the Benjamini-
553	Hochberg procedure. We repeated these enrichments analyses for UKB metabQTL
554	colocalizations, grouped based on metabolite class.

555

#### 556 Colocalization Network

- 557 We constructed a network of all the colocalizations with the T2D meta-analyses using
- 558 cytoscape<sup>82</sup> and measured network properties using cytoNCA.
- 559

#### 560 Effect Direction Consistency

We mapped many of the genes and metabolites identified from a pQTL or metabQTL dataset to multiple T2D index variants. We then measured the consistency of effect estimates for T2D and the pQTL or metabQTL for genes or metabolites with at least 3 mapped T2D index variants by testing for an association between pQTL or metabQTL effect sizes with T2D effect sizes using an ordinary least squares regression model without an intercept, adjusting for an FDR of 0.05 using the Benjamini-Hochberg procedure.

567

#### 568 **Expression Dataset Preparation**

We downloaded scRNA-seq data from HPAP<sup>45</sup> analyzed it with Scanpy<sup>83</sup> v1.9.3. The published 569 570 data from HPAP we used in this study was pre-QC'ed, clustered, and annotated, and a full description of the HPAP data processing steps can be found in their publication<sup>45</sup>. Briefly, cells 571 572 were filtered to have >500 expressed genes per cell and <15% mitochondrial reads. After, 573 ambient RNA was adjusted using SoupX, followed by batch correction with Harmony and 574 clustering using the Leiden algorithm with a resolution of 0.5. Cell types were defined by 575 pseudo-bulking each cell type and identifying marker genes identified with a Wald test. We 576 subset cells from healthy and T2D donors and created pseudobulks per sample by summing 577 raw counts across cells per cell-type. We only kept pseudobulks with at least 5×10<sup>5</sup> counts and 578 from adult individuals (age  $\geq$  20 years; N=21 for healthy and N=17 for T2D). We performed the DE analysis with edgeR<sup>84</sup> v3.40.2. We removed lowly expressed genes per cell-type with 579 580 filterByExpr, which removes genes with less than 10 counts in 10 samples or 15 counts in all 581 samples, using diabetes status as a stratification covariate. After filtering, we tested a total of

582	9,995 genes in acinar cells, 8,150 genes in active stellate cells, 13,171 genes in alpha cells,
583	13,095 genes in beta cells, and 9,422 genes in ductal cells. We then fit a generalized linear
584	model with robust dispersion to the data, using as covariates diabetes status, age, sex, sex and
585	age interaction, self-reported race and ethnicity, and sequencing chemistry. We next used the
586	gImLRT function to identify T2D differentially expressed genes incorporating the dispersion
587	estimates and adjusted the p-values with the Benjamini-Hochberg procedure.
588	
589	We pulled bulk expression dataset for human islets from Marselli et al.44, including 28 T2D
590	cases and 58 ND controls. We performed transcript quantification using salmon 1.4.0 <sup>85</sup> , and
591	differential expression tests using DESeq2 1.38.3 <sup>86</sup> . The DESeq2 results from this study are
592	accessible on GEO under accession number GSE159984.
593	
594	We downloaded bulk expression data of FXYD2 from different iPSC differentiation stages from
595	GEO under the accession number GSE190727. We also downloaded single-cell expression
596	data for stem-cell-derived endocrine cells from Krentz et al. 2018 <sup>42</sup> , Xin et al. 2018 <sup>28</sup> , and
597	Balboa et al. 2022 <sup>43</sup> .
598	
599	Open Targets Drug Identification
600	To identify potential drug repurposing options from our candidate gene list, we queried data files
601	from Open Targets <sup>87</sup> on around 7k drug molecules and around 62k targets, where 4,930 drugs
602	were annotated with 1,538 gene targets. After also retrieving the reported indications of drugs,
603	we refined our search to the approved drugs, which were not withdrawn and did list indications.
604	Open Targets used drug annotations from ChEMBL to define drugs as being approved for an

605 indication if they come from a source of approved drug information (e.g. FDA, WHO ATC, EMA,

- 606 BNF). To test if diabetes drugs were identified more often than expected by chance, we
- 607 compared the drugs targeting our query genes and those targeting all documented non-query

genes using chi-squared tests. Additionally, we tested if permuted 100k random samples from
the same gene list would identify diabetes drug targets at the same rate, sampling 42,539
known genes with HGNC gene symbols and comparing the results from our query gene set and
the random samples.

612

#### 613 Acknowledgement

614 A.H. is supported by the American Diabetes Association grant #11-23-PDF-35. O.B. has 615 received funding from the European Union's Horizon 2020 research and innovation programme 616 under Grant Agreement No 101017802 (OPTOMICS). A.P. is supported by the Wiener-Anspach 617 Foundation, and the Fonds National de la Recherche Scientifique (FNRS). J.B.M is supported 618 by NIDDK (U01DK078616 and R01DK078616). J.M.M. is supported by American Diabetes 619 Association Innovative and Clinical Translational Award 1-19-ICTS-068, American Diabetes 620 Association grant #11-22-ICTSPM-16, by NHGRI (U01HG011723), NIDDK (UM1-DK078616) 621 and Medical University of Bialystok (MUB) grant from the Ministry of Science and Higher 622 Education (Poland). This study also supported in part by the National Center for Advancing 623 Translational Sciences, CTSI grant UL1TR001881, and the National Institute of Diabetes and 624 Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the 625 Southern California Diabetes Endocrinology Research Center. Infrastructure for the CHARGE 626 Consortium is supported in part by the National Heart, Lung, and Blood Institute (NHLBI) grant 627 R01HL105756. This research was conducted in part using data and resources from the 628 Framingham Heart Study of the National Heart Lung and Blood Institute of the National 629 Institutes of Health and Boston University School of Medicine. The Framingham Heart Study 630 (FHS) acknowledges the support of contracts NO1-HC-25195, HHSN2682015000011 and 631 75N92019D00031 from the National Heart, Lung and Blood Institute and grant supplement R01 632 HL092577-06S1 for this research. We also acknowledge the dedication of the FHS study 633 participants without whom this research would not be possible.

#### 634

#### 635 **Disclosures**

- 536 J.B.M is an academic associate for Quest Diagnostics Inc. Endocrine R&D. MIMcC is now an
- 637 employee of Genentech and a holder of Roche stock.
- 638

#### 639 **Contributions**

- 640 R.M. Performed eQTL colocalization analyses, integrated all the colocalization results, built the
- omics network, and characterized the network. Lead the writing of the manuscript and design of
- 642 figures. Lead the interpretation and discussion of the results, deep dives into specific locus and
- 643 wrote the paper.
- 644 K.M.L. Contributed to design the colocalization pipeline. Performed colocalization analyses with
- 645 GWAS traits. Integrated the colocalization results with the previously described T2D genetic
- 646 clusters. Contributed to interpretation and discussion of the results, deep dive into specific
- 647 locus, design of the figures, discussion of the narrative and writing of the paper.
- 648 X.Y. Performed colocalization analyses with deCODE pQLT, UKB pQTL, METSIM metabQTL.
- 649 Contributed to interpretation and discussion of the results, deep dive into specific locus, design
- of the figures, discussion of the narrative and writing the paper.
- 0.B. Performed colocalization analyses with UKB metabQLT. Supervised the enrichment
- analyses of drug targets using open targets data. Contributed to interpretation and discussion of
- the results, deep dive into specific locus, design of the figures, discussion of the narrative andwriting of the paper.
- 655 A.H. Performed colocalization analyses with blood eQTLs from diverse ancestries. Identified
- and evaluated the contribution of eQTL data from diverse ancestries in identifying effector
- 657 genes as well as the value of using ancestry-specific GWAS meta-analysis in improving the
- 658 identification of effector genes. Contributed to interpretation and discussion of the results, deep
- dive into specific locus, design of the figures, discussion of the narrative and writing the paper.

660 A.L.A Performed colocalization analyses with ROSMAP and HELIC pQLT. Contributed to

- interpretation and discussion of the results, deep dive into specific locus, design of the figures,
- discussion of the narrative and writing the paper.
- A.P. Performed the analysis of differential expression in pancreatic islets in T2D and controls
- and islets in lipoglucotoxic conditions. Performed enrichment analyses of colocalization genes
- with differentially expressed genes. Contributed to interpretation and discussion of the results,
- deep dive into specific locus, design of the figures, discussion of the narrative and wrote the
- 667 paper.
- 668 S.H. Performed the curation and mapping of effector genes to drugs using open targets data.
- 669 Performed the enrichment analyses of effector genes with drug targets. Contributed to
- 670 interpretation and discussion of the results, design of the figures, discussion of the narrative and
- 671 writing of the paper.
- 672 K.Y, K.Hr, Y.T., M.L., H.L, M.C, D.L.E. provided and analyzed functional genomics data related
- 673 from single-cell and pancreatic islets with the FXYD2 locus.
- 674 L.S., K.S., K.Ha., H.J.T, N.W.R., J.B.M, MIMcC, A.M., M.U., C.N.S, M.B, M.V, J.I.R. and A.P.M
- 675 Provided feedback throughout the project and revised the paper.
- 676 R.M., A.P.M, B.V., E.Z and J.M.M conceived and planned the study, supervised and
- 677 coordinated the analyses, and wrote the manuscript.
- 678

#### 679 **Figure Legends**

- **Figure 1: Overview of Project. a)** Genomic regions containing the 1,289 T2D-associated index
- variants from Suzuki et al.<sup>15</sup> were tested for evidence of colocalization with 10 eQTL datasets, 4
- 682 pQTL datasets, 2 metabQTL datasets, and 46 related trait GWAS. Colocalizations were then
- mapped to an interactive network to visualize genes (from an eQTL or pQTL, colored green),
- metabolites (colored orange), or traits (colored purple) with evidence of sharing a causal variant
- 685 with T2D around a index variant (colored yellow). These results were then used in downstream

analyses to identify enrichment with expression datasets, better understand T2D pathways, and
identify drug targets for T2D. b) Upset plot of the 716 T2D index variants mapped to an
association in an eQTL, pQTL, metabQTL, or trait GWAS dataset (with a colocalization PP.H4
>0.8, Methods). c) Bar plot of the number of effector genes, metabolites, and traits identified
from colocalization analyses with T2D.

691 Figure 2: Identification of putative effector genes for T2D. a) Plotted are the number of 692 effector genes for T2D previously identified from colocalization analyses between various T2D 693 GWAS and eQTL datasets. Colors indicate the tissue type of the eQTL dataset and shape 694 indicates major self-reported population group of the eQTL dataset. Gray bars represent the 695 total number of unique transcripts across all colocalization analyses per GWAS. b) Upset plot of 696 the variant to gene mappings identified in each eQTL dataset analyzed. c) Proportion of 697 colocalizations with evidence in one tissue (PP.H4 >0.8) and no positive evidence observed in 698 other tissues (PP.H4 <0.3). d) Example of a colocalization observed only in Pancreatic Islets, 699 for the gene SCTR. Colors indicate LD in EUR populations from 1000G relative to rs2244214. 700 Figure 3: pQTL colocalizations identified in multiple datasets. a) Upset plot of variant to 701 gene mappings identified via colocalization analyses with four different pQTL datasets. b) 702 Correlation of pQTL effect sizes for colocalizations identified in both UKB and deCODE pQTL 703 datasets (Pearson R=0.93; P=9.1×10<sup>-17</sup>). c) Locus compare plot of CBLN4 using deCODE 704 pQTL data. d) Colocalization subnetwork of rs1415287, containing the colocalizations with 705 CBLN4 as well as a colocalization with IGFBP-1. Green nodes represent genes from an eQTL 706 or pQTL, orange nodes represent metabolites, purple nodes represent traits, and yellow nodes 707 represent T2D index variants. Size of the nodes indicate the number of colocalizations observed 708 in the full network. Gray edges represent colocalizations with a plasma/blood dataset, green 709 edges represent colocalizations with a subcutaneous adipose eQTL dataset, and pink edges 710 represent colocalizations with a trait. Dashed lines indicate colocalizations are in the opposite

direction as T2D risk and solid lines indicate colocalizations are in the same direction as T2Drisk.

713 Figure 4: eQTL from understudied populations identify novel colocalizations with T2D. a) 714 Upset plot of colocalizations identified with blood eQTL datasets from four different populations. 715 Orange bars represent colocalizations observed only in the Puerto Rican (PR), Mexican 716 American (MX), or African American (AA) datasets (PP.H4 >0.8) and not in the European (EUR) 717 dataset (PP.H4 < 0.3). Blue bars represent colocalizations observed only in the EUR dataset 718 (PP.H4 >0.8) and not in PR, MX, or AA datasets (PP.H4 <0.3). Gray bars represent 719 colocalizations observed in any of the PR, MX, or AA datasets and showed a PP.H4 between 720 0.3 and 0.8 in the European dataset, or were observed in the European dataset but showed a 721 PP.H4 between 0.3 and 0.8 in any of the PR, MX, or AA datasets. b) Log-fold change of allele 722 frequencies between AMR-like and EUR-like populations for T2D index variants with a 723 colocalization observed in one population group. c) Locus compare plots of LIN7A and ACSS3 724 with MX data. Colors indicate LD in AMR continental ancestry from 1000G relative to variant 725 rs10128882. d) Allele frequencies of lead colocalizing variant rs10128882 (blue) and T2D index 726 variant rs11114650 (black) per continental ancestry and per inferred local ancestry among AMR 727 participants from gnomAD v4.0. e) Effect sizes of rs10128882 (blue) and rs11114650 (black) in 728 both the T2D GWAS and blood eQTL datasets, stratified by ancestry. 729 Figure 5: Phosphatidylcholine has consistent negative effect directions with T2D risk. a)

Joint scatterplot of metabolites comparing the number of T2D-associated index variants they are mapped to compared to the change in T2D effect size per change in metabQTL effect size across the variants. Points are colored and sized by Benjamoni-Hochberg adjusted p-value. **b**) Increased glucose has consistent correlation with increased T2D risk at colocalizing index variants. **c**) Decreased phosphatidylcholine has consistent correlation with decreased T2D risk at index variants. **d**) Subnetwork of all colocalizations mapped to a Phosphatidylcholine-mapped T2D-associated index variant. Green nodes represent genes from an eQTL or pQTL, orange

nodes represent metabolites, purple nodes represent traits, and yellow nodes represent T2D
index variants. Size of the nodes indicate the number of colocalizations observed in the full
network.

740 Figure 6: Type 2 Diabetes Clusters Match Trait Colocalizations. a) left panel: Color 741 indicates the percentage of total SNPs with a colocalization in each cluster; each row was a trait 742 used for clustering. Final rows list total number of SNPs in each cluster and the total % of SNPs 743 in the cluster with at least one colocalization. right panel: Color indicates the percentage of 744 colocalizing SNPs who have the same (red) or opposite (blue) effect direction as the linked T2D 745 SNP, with white indicating that SNPs are split 50/50 for direction, and gray indicating there were no colocalizations between that trait and any SNPs in that cluster. Text in each square indicates 746 747 the total number of SNPs in that cluster that colocalize with that trait. b) Upset plot of all 748 colocalizing SNPs with 2 or more trait group colocalizations showing trait group overlaps, with 749 bars colored by cluster membership. c) Upset plot showing trait group overlaps for colocalizing 750 SNPs in the lipodystrophy cluster, with gold bars highlighting overlaps that include 4 or more 751 trait groups (n=19 out of 27 colocalizing SNPs).

752 Figure 7: Identification of novel drug targets for T2D. a) Forest plot of chi2 enrichment 753 results between drugs targeting colocalizing genes identified in at least one dataset (all), only 754 from an eQTL, only from a pQTL, and only from a *trans*-pQTL with drugs having an approved 755 indication of diabetes in Open Targets. b) Forest plot of enrichment results using drugs having 756 an indication of diabetes. c) Locus compare plot of FXYD2, identified from a colocalization 757 observed only with pancreatic islet eQTL data. d) Violin plot of FXYD2 expression per rs529623 758 genotype. e) Violin plot of FXYD2 expression among people with T2D and non-diabetes (ND) 759 stratified by weight status in bulk pancreatic islet data. f) Violin plot of FXYD2 expression from 760 human donor single-cell pancreatic islet data stratified by cell-type. Adjusted P-values < 0.001 761 are indicated with "\*\*", and adjusted P-values <0.05 with "\*". Due to the low number of cells per 762 sample, the differential expression test was not performed for some cell types (Methods).

763

764	Extended Data Figure 1: eQTL colocalizations correlate with sample size. Scatter plot of
765	the number of colocalizations between the T2D multi-ancestry meta-analysis and different eQTL
766	datasets compared to the sample size of the eQTL datasets.
767	Extended Data Figure 2: Enrichment of pancreatic islet colocalizing effector transcripts
768	in differential gene expression data. GSEA plots of colocalizing effector transcripts with
769	differentially expressed genes from the bulk human pancreatic islet dataset, stratified by
770	whether the T2D index variant risk allele is associated with increases (same direction) or
771	decreases (opposite direction) of gene expression.
772	Extended Data Figure 3: IGFBP2 associations with T2D are highly consistent genome-
773	wide. a) Joint scatterplot of proteins comparing the number of T2D-associated index variants
774	they are mapped to compared to the association of pQTL effect sizes to T2D effect sizes across
775	the variants. Points are colored and sized by Benjamoni-Hochberg adjusted p-value. b)
776	Decreased plasma protein levels of insulin growth factor binding protein 2 IGFBP2 has
777	consistent correlation with increased T2D risk at colocalizing lead variants.
778	Extended Data Figure 4: Overlap of T2D clusters with trait, eQTL, and metabQTL
779	colocalizations. Heatmaps of the percent of index variants per cluster mapped to a
780	colocalization with a metabolite group, eQTL dataset, and additional related trait GWAS.
781	Extended Data Figure 5: Colocalizations between index variants and trait groups per T2D
782	genetic cluster. Upset plots of colocalizations between T2D index variants from different T2D
783	genetic clusters with related cardiometabolic trait groups.
784	Extended Data Figure 6: Permutations of overlaps from T2D colocalizing genes with
785	drugs from Open Targets. Ratios of approved diabetes drugs of detected drugs compared to
786	100k random samples (histogram) for a) genes from all T2D colocalizations, b) genes only
787	identified from a T2D coloclization with eQTL, c) genes only identified from a T2D coloclization
788	with pQTL, and d) genes only identified from a T2D coloclization with trans-pQTL. P-values

indicate difference in the approved proportion of diabetes indications per drug for colocalizingquery genes relative to random permutations.

791 Extended Data Figure 7: *FXYD2* expression in islet progenitor cells. a) Heatmap of *FXYD2* 

- repression throughout various stages of iPSC differentiation into beta-like cells, where colors
- correspond to the log<sub>2</sub>(TPM+1) expression level of an individual sample (1-5). The differentiation
- stages include definitive endoderm (DE), pancreatic progenitor (PP), stem cell-derived islets at
- stage 7 (SC-islets) and the islets following grafting into immune deficient mice for 4 months
- (graft). **b)** Dot plot showing mean gene expression of FXYD2 and INS in the endocrine cell
- clusters in the integrated dataset of 46,261 stem-cell-derived endocrine cells and adult human
- islet cells (Krentz et al. 2018, Xin et al. 2018, and Balboa et al. 2022). Dot size is relative to the
- fraction of cells within a cluster expressing the gene. Endocrine Prog., Endocrine progenitors;
- 800 SC-EC, Stem-cell-derived enterochromaffin-like cells; SC-Beta, Stem-cell-derived beta cells;
- 801 SC-Alpha, Stem-cell-derived alpha cells.
- 802
- Herman, W. H. & Zimmet, P. Type 2 Diabetes: An Epidemic Requiring Global Attention and
   Urgent Action. *Diabetes Care* 35, 943–944 (2012).
- Jaacks, L. M., Siegel, K. R., Gujral, U. P. & Narayan, K. M. V. Type 2 diabetes: A 21st
   century epidemic. *Best Pract. Res. Clin. Endocrinol. Metab.* **30**, 331–343 (2016).
- 807 3. Rusina, P. V. *et al.* Genetic support for FDA-approved drugs over the past decade. *Nat.*808 *Rev. Drug Discov.* 22, 864–864 (2023).
- Minikel, E. V., Painter, J. L., Dong, C. C. & Nelson, M. R. Refining the impact of genetic
  evidence on clinical success. *Nature* 1–6 (2024) doi:10.1038/s41586-024-07316-0.
- 5. Duffy, Á. *et al.* Development of a human genetics-guided priority score for 19,365 genes and
  399 drug indications. *Nat. Genet.* 56, 51–59 (2024).
- 813 6. Wang, X. *et al.* The impact on clinical success from the 23andMe cohort.
- 814 2024.06.17.24309059 Preprint at https://doi.org/10.1101/2024.06.17.24309059 (2024).

815	7. Karczewski, K. J. et al. Systematic single-variant and gene-based association testing of
816	thousands of phenotypes in 394,841 UK Biobank exomes. Cell Genomics 2, (2022).
817	8. Wang, Q. et al. Rare variant contribution to human disease in 281,104 UK Biobank exomes.
818	Nature <b>597</b> , 527–532 (2021).
819	9. Flannick, J. et al. Exome sequencing of 20,791 cases of type 2 diabetes and
820	24,440 controls. Nature 570, 71–76 (2019).
821	10. Mahajan, A. et al. Fine-mapping type 2 diabetes loci to single-variant resolution using high-
822	density imputation and islet-specific epigenome maps. Nat. Genet. 50, 1505–1513 (2018).
823	11. Mahajan, A. et al. Multi-ancestry genetic study of type 2 diabetes highlights the power of
824	diverse populations for discovery and translation. Nat. Genet. 54, 560–572 (2022).
825	12. Spracklen, C. N. et al. Identification of type 2 diabetes loci in 433,540 East Asian individuals.
826	Nature <b>582</b> , 240–245 (2020).
827	13. Suzuki, K. et al. Identification of 28 new susceptibility loci for type 2 diabetes in the
828	Japanese population. Nat. Genet. 51, 379–386 (2019).
829	14. Vujkovic, M. et al. Discovery of 318 new risk loci for type 2 diabetes and related vascular
830	outcomes among 1.4 million participants in a multi-ancestry meta-analysis. Nat. Genet. 52,

831680–691 (2020).

- 832 15. Suzuki, K. *et al.* Genetic drivers of heterogeneity in type 2 diabetes pathophysiology. *Nature*833 1–11 (2024) doi:10.1038/s41586-024-07019-6.
- 16. Mahajan, A. *et al.* Refining the accuracy of validated target identification through coding
  variant fine-mapping in type 2 diabetes. *Nat. Genet.* **50**, 559–571 (2018).
- 836 17. Broadaway, K. A. *et al.* Loci for insulin processing and secretion provide insight into type 2
  837 diabetes risk. *Am. J. Hum. Genet.* **110**, 284–299 (2023).
- 18. Viñuela, A. *et al.* Genetic variant effects on gene expression in human pancreatic islets and
  their implications for T2D. *Nat. Commun.* **11**, 4912 (2020).

- 840 19. Alonso, L. *et al.* TIGER: The gene expression regulatory variation landscape of human
  841 pancreatic islets. *Cell Rep.* 37, (2021).
- 842 20. Nguyen, J. P. *et al.* eQTL mapping in fetal-like pancreatic progenitor cells reveals early
- developmental insights into diabetes risk. *Nat. Commun.* **14**, 6928 (2023).
- 21. Smith, K. *et al.* Multi-ancestry polygenic mechanisms of type 2 diabetes. *Nat. Med.* 1–10
- 845 (2024) doi:10.1038/s41591-024-02865-3.
- 846 22. Kachuri, L. et al. Gene expression in African Americans, Puerto Ricans and Mexican
- 847 Americans reveals ancestry-specific patterns of genetic architecture. Nat. Genet. 55, 952–
- 848 963 (2023).

849 23. THE GTEX CONSORTIUM. The GTEx Consortium atlas of genetic regulatory effects across
850 human tissues. *Science* 369, 1318–1330 (2020).

- 851 24. Gloudemans, M. J. et al. Integration of genetic colocalizations with physiological and
- pharmacological perturbations identifies cardiometabolic disease genes. *Genome Med.* 14,
- 853 31 (2022).
- 25. Solimena, M. et al. Systems biology of the IMIDIA biobank from organ donors and
- 855 pancreatectomised patients defines a novel transcriptomic signature of islets from
- individuals with type 2 diabetes. *Diabetologia* **61**, 641–657 (2018).
- 26. Ferrannini, E. *et al.* Mechanisms of Sodium–Glucose Cotransporter 2 Inhibition: Insights
- 858 From Large-Scale Proteomics. *Diabetes Care* **43**, 2183–2189 (2020).

859 27. Wittenbecher, C. *et al.* Insulin-Like Growth Factor Binding Protein 2 (IGFBP-2) and the Risk

- of Developing Type 2 Diabetes. *Diabetes* **68**, 188–197 (2018).
- 861 28. Xin, Y. *et al.* Pseudotime Ordering of Single Human β-Cells Reveals States of Insulin
- 862 Production and Unfolded Protein Response. *Diabetes* **67**, 1783–1794 (2018).
- 863 29. Yang, J. et al. Circulating IGFBP-2 levels are inversely associated with the incidence of
- nonalcoholic fatty liver disease: A cohort study. J. Int. Med. Res. 48, 0300060520935219
- 865 (2020).

- 30. Fahlbusch, P. et al. Physiological Disturbance in Fatty Liver Energy Metabolism Converges
- 867 on IGFBP2 Abundance and Regulation in Mice and Men. *Int. J. Mol. Sci.* **21**, 4144 (2020).
- 31. Arruda, A. L., Morris, A. P. & Zeggini, E. Advancing equity in human genomics through
- tissue-specific multi-ancestry molecular data. *Cell Genomics* **4**, 100485 (2024).
- 870 32. Olsen, O., Wade, J. B., Morin, N., Bredt, D. S. & Welling, P. A. Differential localization of
- 871 mammalian Lin-7 (MALS/Veli) PDZ proteins in the kidney. Am. J. Physiol. Renal Physiol.
- 872 **288**, F345-352 (2005).
- 873 33. Jia, Z. et al. ACSS3 in brown fat drives propionate catabolism and its deficiency leads to
- autophagy and systemic metabolic dysfunction. *Clin. Transl. Med.* **12**, e665 (2022).
- 875 34. Virtanen, J. K., Tuomainen, T.-P. & Voutilainen, S. Dietary intake of choline and
- phosphatidylcholine and risk of type 2 diabetes in men: The Kuopio Ischaemic Heart
  Disease Risk Factor Study. *Eur. J. Nutr.* **59**, 3857–3861 (2020).
- 878 35. Wong, T. H. T. *et al.* A two-sample Mendelian randomization study explores metabolic
- profiling of different glycemic traits. *Commun. Biol.* **7**, 1–9 (2024).
- 36. Opreanu, M. et al. The Unconventional Role of Acid Sphingomyelinase in Regulation of
- Retinal Microangiopathy in Diabetic Human and Animal Models. *Diabetes* 60, 2370–2378
  (2011).
- 37. Minikel, E. V., Painter, J. L., Dong, C. C. & Nelson, M. R. Refining the impact of genetic
  evidence on clinical success. 2023.06.23.23291765 Preprint at
- 885 https://doi.org/10.1101/2023.06.23.23291765 (2023).
- 38. Sadler, M. C., Auwerx, C., Deelen, P. & Kutalik, Z. Multi-layered genetic approaches to
  identify approved drug targets. *Cell Genomics* 3, 100341 (2023).
- 39. Flamez, D. *et al.* A genomic-based approach identifies FXYD domain containing ion
- transport regulator 2 (FXYD2)gammaa as a pancreatic beta cell-specific biomarker.
- 890 *Diabetologia* **53**, 1372–1383 (2010).

- 40. Wetzel, R. K., Pascoa, J. L. & Arystarkhova, E. Stress-induced Expression of the γ Subunit
- (FXYD2) Modulates Na,K-ATPase Activity and Cell Growth\*. *J. Biol. Chem.* 279, 41750–
  41757 (2004).
- 41. Chandra, V. *et al.* The type 1 diabetes gene TYK2 regulates β-cell development and its
  responses to interferon-α. *Nat. Commun.* **13**, 6363 (2022).
- 42. Krentz, N. A. J. et al. Single-Cell Transcriptome Profiling of Mouse and hESC-Derived
- 897 Pancreatic Progenitors. *Stem Cell Rep.* **11**, 1551–1564 (2018).
- 43. Balboa, D. et al. Functional, metabolic and transcriptional maturation of human pancreatic
- islets derived from stem cells. *Nat. Biotechnol.* **40**, 1042–1055 (2022).
- 900 44. Marselli, L. *et al.* Persistent or Transient Human β Cell Dysfunction Induced by Metabolic
- 901 Stress: Specific Signatures and Shared Gene Expression with Type 2 Diabetes. *Cell Rep.*

**33**, (2020).

- 903 45. Elgamal, R. M. *et al.* An Integrated Map of Cell Type–Specific Gene Expression in
- 904 Pancreatic Islets. *Diabetes* **72**, 1719–1728 (2023).
- 905 46. Kopf, D. *et al.* Insulin Secretion and Sensitivity after Single-Dose Amisulpride, Olanzapine or
- 906 Placebo in Young Male Subjects: Double Blind, Cross-Over Glucose Clamp Study.
- 907 *Pharmacopsychiatry* **45**, 223–228 (2012).
- 47. Glunk, V. *et al.* A non-coding variant linked to metabolic obesity with normal weight affects
  actin remodelling in subcutaneous adipocytes. *Nat. Metab.* 5, 861–879 (2023).
- 910 48. Rusu, V. *et al.* Type 2 Diabetes Variants Disrupt Function of SLC16A11 through Two
- 911 Distinct Mechanisms. *Cell* **170**, 199-212.e20 (2017).
- 912 49. Rottner, A. K. et al. A genome-wide CRISPR screen identifies CALCOCO2 as a regulator of
- 913 beta cell function influencing type 2 diabetes risk. *Nat. Genet.* **55**, 54–65 (2023).
- 914 50. Dwivedi, O. P. et al. Loss of ZnT8 function protects against diabetes by enhanced insulin
- 915 secretion. *Nat. Genet.* **51**, 1596–1606 (2019).

- 916 51. Thomsen, S. K. *et al.* Type 2 diabetes risk alleles in PAM impact insulin release from human
  917 pancreatic β-cells. *Nat. Genet.* **50**, 1122–1131 (2018).
- 918 52. Abifadel, M. et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.
- 919 Nat. Genet. **34**, 154–156 (2003).
- 920 53. Santer, R. & Calado, J. Familial renal glucosuria and SGLT2: from a mendelian trait to a
- 921 therapeutic target. *Clin. J. Am. Soc. Nephrol. CJASN* **5**, 133–141 (2010).
- 54. Chen, J. *et al.* The trans-ancestral genomic architecture of glycemic traits. *Nat. Genet.* 53,
  840–860 (2021).
- 55. Graham, S. E. *et al.* The power of genetic diversity in genome-wide association studies of
  lipids. *Nature* 600, 675–679 (2021).
- 926 56. Sakaue, S. et al. A cross-population atlas of genetic associations for 220 human
- 927 phenotypes. *Nat. Genet.* **53**, 1415–1424 (2021).
- 928 57. Sulc, J. et al. Composite trait Mendelian randomization reveals distinct metabolic and
- 929 lifestyle consequences of differences in body shape. *Commun. Biol.* **4**, 1–13 (2021).
- 930 58. Liu, Y. *et al.* Genetic architecture of 11 organ traits derived from abdominal MRI using deep
- 931 learning. *eLife* **10**, e65554 (2021).
- 932 59. Warrington, N. M. *et al.* Maternal and fetal genetic effects on birth weight and their
- 933 relevance to cardio-metabolic risk factors. *Nat. Genet.* **51**, 804–814 (2019).
- 60. Agrawal, S. *et al.* Inherited basis of visceral, abdominal subcutaneous and gluteofemoral fat
- 935 depots. *Nat. Commun.* **13**, 3771 (2022).
- 936 61. Evangelou, E. et al. Genetic analysis of over 1 million people identifies 535 new loci
- 937 associated with blood pressure traits. *Nat. Genet.* **50**, 1412–1425 (2018).
- 938 62. Stanzick, K. J. et al. Discovery and prioritization of variants and genes for kidney function in
- 939 >1.2 million individuals. *Nat. Commun.* **12**, 4350 (2021).
- 940 63. Teumer, A. *et al.* Genome-wide association meta-analyses and fine-mapping elucidate
- 941 pathways influencing albuminuria. *Nat. Commun.* **10**, 4130 (2019).

- 942 64. Hartiala, J. A. *et al.* Genome-wide analysis identifies novel susceptibility loci for myocardial
- 943 infarction. *Eur. Heart J.* **42**, 919–933 (2021).
- 944 65. Jiang, L., Zheng, Z., Fang, H. & Yang, J. A generalized linear mixed model association tool
- 945 for biobank-scale data. *Nat. Genet.* **53**, 1616–1621 (2021).
- 946 66. Sandholm, N. *et al.* Genome-wide meta-analysis and omics integration identifies novel
- genes associated with diabetic kidney disease. *Diabetologia* **65**, 1495–1509 (2022).
- 948 67. van Zuydam, N. R. *et al.* Genome-Wide Association Study of Peripheral Artery Disease.
- 949 *Circ. Genomic Precis. Med.* **14**, e002862 (2021).
- 950 68. Wuttke, M. et al. A catalog of genetic loci associated with kidney function from analyses of a
- 951 million individuals. *Nat. Genet.* **51**, 957–972 (2019).
- 952 69. Liu, H. et al. Epigenomic and transcriptomic analyses define core cell types, genes and
- targetable mechanisms for kidney disease. *Nat. Genet.* **54**, 950–962 (2022).
- 954 70. Malik, R. *et al.* Multiancestry genome-wide association study of 520,000 subjects identifies
- 955 32 loci associated with stroke and stroke subtypes. *Nat. Genet.* **50**, 524–537 (2018).
- 956 71. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of
- genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).
- 958 72. Ferkingstad, E. et al. Large-scale integration of the plasma proteome with genetics and
- 959 disease. *Nat. Genet.* **53**, 1712–1721 (2021).
- 960 73. Sun, B. B. *et al.* Plasma proteomic associations with genetics and health in the UK Biobank.
  961 *Nature* 622, 329–338 (2023).
- 962 74. Panoutsopoulou, K. *et al.* Genetic characterization of Greek population isolates reveals
- 963 strong genetic drift at missense and trait-associated variants. *Nat. Commun.* **5**, 5345 (2014).
- 964 75. Png, G. et al. Identifying causal serum protein-cardiometabolic trait relationships using
- 965 whole genome sequencing. *Hum. Mol. Genet.* **32**, 1266–1275 (2023).
- 966 76. Png, G. *et al.* Mapping the serum proteome to neurological diseases using whole genome
- 967 sequencing. *Nat. Commun.* **12**, 7042 (2021).

- 968 77. Gilly, A. *et al.* Genome-wide meta-analysis of 92 cardiometabolic protein serum levels. *Mol.*969 *Metab.* 78, 101810 (2023).
- 970 78. Robins, C. *et al.* Genetic control of the human brain proteome. *Am. J. Hum. Genet.* **108**,
- 971 400–410 (2021).
- 972 79. Yin, X. *et al.* Genome-wide association studies of metabolites in Finnish men identify
  973 disease-relevant loci. *Nat. Commun.* **13**, 1644 (2022).
- 80. Borges, M. C. et al. Role of circulating polyunsaturated fatty acids on cardiovascular
- 975 diseases risk: analysis using Mendelian randomization and fatty acid genetic association
- 976 data from over 114,000 UK Biobank participants. *BMC Med.* **20**, 210 (2022).
- 977 81. Giambartolomei, C. et al. Bayesian Test for Colocalisation between Pairs of Genetic
- 978 Association Studies Using Summary Statistics. *PLOS Genet.* **10**, e1004383 (2014).
- 82. Shannon, P. *et al.* Cytoscape: a software environment for integrated models of biomolecular
  interaction networks. *Genome Res.* 13, 2498–2504 (2003).
- 83. Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression
  data analysis. *Genome Biol.* 19, 15 (2018).
- 983 84. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for
- 984 differential expression analysis of digital gene expression data. *Bioinformatics* 26, 139–140
  985 (2010).
- 85. Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and
  bias-aware quantification of transcript expression. *Nat. Methods* 14, 417–419 (2017).
- 86. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for
  RNA-seq data with DESeq2. *Genome Biol.* 15, 550 (2014).
- 87. Ochoa, D. *et al.* Open Targets Platform: supporting systematic drug-target identification and
  prioritisation. *Nucleic Acids Res.* 49, D1302–D1310 (2021).
- 992

# Figure 1



## medRxiv preprint doi: https://doi.org/10.1101/2024.07.15.24310282; this version posted July 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.



Set size

# Integration with **Expression Datasets**

Characterization of T2D molecular pathways

> Identification of novel drug targets

### Figure 2 **a**



### Figure 3







-1.0 -0.6 Normalized effect size

Normalized effect size

### Figure 5





Trait



20 15 10 5 0 Set size

Lipids Adipose Anthropometric Glycaemic Liver Biomarkers Blood Pressure

....

Colocalizations by Variant

